The 2022 Ogawa-Yamanaka Stem Cell Prize Awarded to Juan Carlos Izpisua Belmonte
/PRNewswire/ -- Juan Carlos Izpisua Belmonte, PhD, was announced today as the recipient of the 2022 Ogawa-Yamanaka Stem Cell Prize by Gladstone Institutes....
Stay updated with breaking news from Lorenz Studer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Juan Carlos Izpisua Belmonte, PhD, was announced today as the recipient of the 2022 Ogawa-Yamanaka Stem Cell Prize by Gladstone Institutes....
/PRNewswire/ -- Juan Carlos Izpisua Belmonte, PhD, was announced today as the recipient of the 2022 Ogawa-Yamanaka Stem Cell Prize by Gladstone Institutes....
Share Projects funded by the New York State Stem Cell Science program included ones studying human embryonic stem cells (center). Science Source New York state ends stem cell research funding Apr. 16, 2021 , 3:45 PM Over the past decade, New York state has become an international hub of stem cell research. In part, that’s thanks to one of the United States’s only state-level programs devoted exclusively to this area of science, researchers say. But now, New York’s state government has killed the program, which scientists fear will slow research progress and cause a brain drain t...
16 Feb 2021 In the brain, complex interactions between different cell types can drive inflammation and disease. This cross talk is hard to study in vitro, because culture systems are often too simple to recapitulate the intricacies of the brain, or the mix of cells is too poorly defined to give reliable results. In the February 8 Nature Neuroscience, researchers led by Lorenz Studer at the Sloan Kettering Institute for Cancer Research in New York City describe a triculture system of neurons, microglia, and astrocytes that combines pure populations of each cell type in a defined ratio. Generat...
BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson's Disease News provided by Share this article Share this article CAMBRIDGE, Mass., Jan. 7, 2021 /PRNewswire/ -- BlueRock Therapeutics, a preclinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, in collaboration with Memorial Sloan Kettering Cancer Center (MSK), announced today that the U.S. Food and Drug Administration (FDA) has cleared their Investigational New Drug (IND) application to proceed with a Phase 1 (Ph1) study in ...